Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.

Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, Veerapal C, Khan N, Cherian K, Felber E, Brown R, Choi E, King S, Pankow H, Bishop JH, Azeez A, Coetzee J, Rapier R, Odenwald N, Carreon D, Hawkins J, Chang M, Keller J, Raj K, DeBattista C, Jo B, Espil FM, Schatzberg AF, Sudheimer KD, Williams NR (2022) The American journal of psychiatry
Title and abstract of Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.

Key Takeaway

SAINT protocol achieved 79% remission rate in treatment-resistant depression with effects appearing within days.

Summary

This landmark study evaluated the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol for treatment-resistant depression.

Key findings:

  • 79% remission rate (vs 13% sham)
  • 90% response rate
  • Effects appeared within 5 days
  • Sustained at 4-week follow-up

Protocol:

  • 10 sessions per day for 5 days
  • Intermittent theta burst stimulation
  • fMRI-guided targeting
  • 90,000 total pulses

Patient population:

  • Treatment-resistant depression
  • Failed 2+ antidepressant trials
  • Moderate to severe symptoms

Safety:

  • No serious adverse events
  • Mild headache most common side effect
  • No cognitive impairment

Clinical significance:

Represents major breakthrough in depression treatment, demonstrating that accelerated TMS can achieve rapid remission in previously treatment-resistant patients.

Figures

Related Interventions

Related Studies

Source

View on PubMed →

DOI: 10.1176/appi.ajp.2021.20101429